An open-label randomized, controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19 – Final results from the DisCoVeRy trial

Florence Ader; Nathan Peiffer-Smadja; Julien Poissy; Maude Bouscambert-Duchamp; Drifa Belhadi; Alpha Diallo; Christelle Delmas; Juliette Saillard; Aline Dechanet; Noémie Mercier; Axelle Dupont; Toni Alfaiate; François-Xavier Lescure; François Raffi; François Goehringer; Antoine Kimmoun; Stéphane Jaureguiberry; Jean Reignier; Saad Nseir; François Danion; Raphael Clere-Jehl; Kévin Bouiller; Jean-Christophe Navellou; Violaine Tolsma; André Cabie; Clément Dubost; Johan Courjon; Sylvie Leroy; Joy Mootien; Rostane Gaci; Bruno Mourvillier; Emmanuel Faure; Valérie Pourcher; Sébastien Gallien; Odile Launay; Karine Lacombe; Jean-Philippe Lanoix; Alain Makinson; Guillaume Martin-Blondel; Lila Bouadma; Elisabeth Botelho-Nevers; Amandine Gagneux-Brunon; Olivier Epaulard; Lionel Piroth; Florent Wallet; Jean-Christophe Richard; Jean Reuter; Thérèse Staub; Bruno Lina; Marion Noret; Claire Andrejak; Minh Patrick Lê; Gilles Peytavin; Maya Hites; Dominique Costagliola; Yazdan Yazdanpanah; Charles Burdet; France Mentre

bioRxiv (2022) - Comments
doi: 10.1101/2022.02.16.22271064

Florence Ader, Nathan Peiffer-Smadja, Julien Poissy, Maude Bouscambert-Duchamp, Drifa Belhadi, Alpha Diallo, Christelle Delmas, Juliette Saillard, Aline Dechanet, Noémie Mercier, Axelle Dupont, Toni Alfaiate, François-Xavier Lescure, François Raffi, François Goehringer, Antoine Kimmoun, Stéphane Jaureguiberry, Jean Reignier, Saad Nseir, François Danion